Low-volume insulin degludec [amount hidden] once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial

What Was Tested

This randomized controlled trial paper looks at Insulin Glargine.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized and open-label study.

Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.

Nothing was hidden in this open-label Insulin Glargine study: the participants and staff both knew the treatment.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents, Insulin and Insulin, Long-Acting.

What This Means in Plain Language

The paper is a randomized and open-label study of Insulin Glargine.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Diabetes care), a journal based in United States.

More context: the Insulin Glargine compound page, all human trials.